JP2018514550A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018514550A5 JP2018514550A5 JP2017556651A JP2017556651A JP2018514550A5 JP 2018514550 A5 JP2018514550 A5 JP 2018514550A5 JP 2017556651 A JP2017556651 A JP 2017556651A JP 2017556651 A JP2017556651 A JP 2017556651A JP 2018514550 A5 JP2018514550 A5 JP 2018514550A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ctla
- antibody according
- administered
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021037367A JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2024018579A JP2024063023A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562153973P | 2015-04-28 | 2015-04-28 | |
| US62/153,973 | 2015-04-28 | ||
| PCT/US2016/029877 WO2016176503A1 (en) | 2015-04-28 | 2016-04-28 | Treatment of pd-l1-negative melanoma using an anti-pd-1 antibody and an anti-ctla-4 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037367A Division JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018514550A JP2018514550A (ja) | 2018-06-07 |
| JP2018514550A5 true JP2018514550A5 (https=) | 2019-06-13 |
Family
ID=56087499
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556651A Pending JP2018514550A (ja) | 2015-04-28 | 2016-04-28 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2021037367A Pending JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2024018579A Pending JP2024063023A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021037367A Pending JP2021105000A (ja) | 2015-04-28 | 2021-03-09 | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| JP2024018579A Pending JP2024063023A (ja) | 2015-04-28 | 2024-02-09 | 抗ｐｄ－１抗体および抗ｃｔｌａ－４抗体を使用するｐｄ－ｌ１陰性黒色腫の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US10174113B2 (https=) |
| EP (2) | EP3288982A1 (https=) |
| JP (3) | JP2018514550A (https=) |
| KR (2) | KR20170138555A (https=) |
| WO (1) | WO2016176503A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HK1203971A1 (en) * | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR20250004095A (ko) * | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| WO2016196389A1 (en) * | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| MX383464B (es) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. |
| EP4458417A3 (en) | 2015-08-11 | 2025-02-19 | Wuxi Biologics Ireland Limited | Novel anti-pd-1 antibodies |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| JP7258747B2 (ja) * | 2016-10-28 | 2023-04-17 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いた尿路上皮癌の処置方法 |
| CN110300599B (zh) | 2016-12-07 | 2024-07-02 | 艾吉纳斯公司 | 抗体和其使用方法 |
| SG11201908129PA (en) * | 2017-03-17 | 2019-10-30 | Nantomics Llc | LIQUID BIOPSY FOR cfRNA |
| WO2018183408A1 (en) * | 2017-03-31 | 2018-10-04 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer with a combination of an antagonist of pd-1 and an anti-ctla4 antibody |
| TW202444417A (zh) * | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| JP7173993B2 (ja) | 2017-05-19 | 2022-11-17 | ウーシー バイオロジクス（シャンハイ）カンパニー リミテッド | 細胞傷害性ｔリンパ球関連タンパク質４（ｃｔｌａ－４）に対する新規モノクローナル抗体 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| WO2019104327A1 (en) * | 2017-11-27 | 2019-05-31 | Heat Biologics, Inc. | Gp96-based cancer therapy |
| KR102834864B1 (ko) * | 2018-02-02 | 2025-07-16 | 온코씨4, 아이앤씨. | 개선된 면역치료 효과를 갖지만 약화된 부작용을 갖는 돌연변이 항-ctla-4 항체 |
| CA3122773A1 (en) | 2018-12-26 | 2020-07-02 | Xilio Development, Inc. | Anti-ctla4 antibodies and methods of use thereof |
| KR20220026575A (ko) * | 2019-06-25 | 2022-03-04 | 시티 오브 호프 | Pdl1 양성 nk 세포 암 치료 |
| GB201912107D0 (en) | 2019-08-22 | 2019-10-09 | Amazentis Sa | Combination |
| AR122043A1 (es) * | 2020-05-12 | 2022-08-03 | Bristol Myers Squibb Co | Dosificación y administración del anticuerpo anti-ctla-4 activable |
| EP4482947A1 (en) | 2022-02-24 | 2025-01-01 | Amazentis SA | Uses of urolithins |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US7423125B2 (en) | 1995-08-01 | 2008-09-09 | Vegenics Limited | Antibodies to VEGF-C |
| US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| KR100816621B1 (ko) | 1997-04-07 | 2008-03-24 | 제넨테크, 인크. | 항-ｖｅｇｆ 항체 |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| JP2002536968A (ja) | 1999-01-29 | 2002-11-05 | イムクローン システムズ インコーポレイティド | Ｋｄｒに特異的な抗体およびその使用 |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| JP2003520828A (ja) | 2000-01-27 | 2003-07-08 | ジェネティクス インスティテュート，エルエルシー | Ｃｔｌａ４（ｃｄ１５２）に対する抗体、これを含む結合体、およびその使用 |
| EP2298346A3 (en) | 2002-03-04 | 2011-11-16 | Imclone LLC | Human antibodies specific to kdr and uses thereof |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
| CN101102791B (zh) | 2004-11-18 | 2011-12-14 | 英克隆有限责任公司 | 抗血管内皮生长因子受体-1的抗体 |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| CA2611861C (en) | 2005-06-08 | 2017-11-28 | The Brigham And Women's Hospital, Inc. | Methods and compositions for the treatment of persistent infections |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| WO2007113648A2 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| CA2705152C (en) | 2007-11-09 | 2016-10-11 | Peregrine Pharmaceuticals, Inc. | Anti-vegf antibody compositions and methods |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| PL2504364T3 (pl) | 2009-11-24 | 2017-12-29 | Medimmune Limited | Ukierunkowane środki wiążące przeciwko B7-H1 |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| CA2828940C (en) | 2011-03-10 | 2024-04-16 | Provectus Pharmaceuticals, Inc. | Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer |
| WO2012145403A1 (en) | 2011-04-18 | 2012-10-26 | Concentric Rockford Inc. | Velocity control for hydraulic control system |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CA2840018C (en) | 2011-07-24 | 2019-07-16 | Curetech Ltd. | Variants of humanized immunomodulatory monoclonal antibodies |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| PL2904011T3 (pl) | 2012-10-02 | 2018-01-31 | Bristol Myers Squibb Co | Połączenie przeciwciał anty-kir i przeciwciał anty-pd-1 w leczeniu raka |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| JP6595458B2 (ja) | 2013-09-20 | 2019-10-23 | ブリストル−マイヤーズ スクイブ カンパニー | 腫瘍を処置するための抗ｌａｇ−３抗体と抗ｐｄ−１抗体との組合せ |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| WO2015176033A1 (en) | 2014-05-15 | 2015-11-19 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| EP3149043A1 (en) | 2014-05-29 | 2017-04-05 | Medimmune Limited | Antagonists of pdl-1 and pd-1 for the treatment of hpv-negative cancers |
| CA2955612C (en) | 2014-07-18 | 2022-05-17 | Advaxis, Inc. | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer |
| EP3183269A2 (en) | 2014-08-22 | 2017-06-28 | Bristol-Myers Squibb Company | Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody |
| EP3212670B1 (en) | 2014-10-29 | 2020-12-23 | Five Prime Therapeutics, Inc. | Combination therapy for cancer |
| US20180133313A1 (en) | 2014-12-16 | 2018-05-17 | Bristol-Myers Squibb Company | Use of immune checkpoint inhibitors in central nervous systems neoplasms |
| JP2018515474A (ja) | 2015-04-28 | 2018-06-14 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体を使用するｐｄ−ｌ１陽性黒色腫の処置 |
| JP2018514550A (ja) | 2015-04-28 | 2018-06-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 抗ｐｄ−１抗体および抗ｃｔｌａ−４抗体を使用するｐｄ−ｌ１陰性黒色腫の処置 |
| DK3303396T5 (da) | 2015-05-29 | 2024-10-07 | Bristol Myers Squibb Co | Antistoffer mod ox40 og anvendelser deraf |
| WO2016196389A1 (en) | 2015-05-29 | 2016-12-08 | Bristol-Myers Squibb Company | Treatment of renal cell carcinoma |
| EP3322731B1 (en) | 2015-07-14 | 2021-01-13 | Bristol-Myers Squibb Company | Method of treating cancer using immune checkpoint inhibitor; antibody that binds to programmed death-1 receptor (pd-1) or programmed death ligand 1 (pd-l1) |
| US10392442B2 (en) | 2015-12-17 | 2019-08-27 | Bristol-Myers Squibb Company | Use of anti-PD-1 antibody in combination with anti-CD27 antibody in cancer treatment |
| US20210206854A1 (en) | 2016-01-27 | 2021-07-08 | Bristol-Myers Squibb Company | Treatment of lung cancer using a combination of an anti-pd-1 antibody and another anti-cancer agent |
| JP2019517512A (ja) | 2016-06-03 | 2019-06-24 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 結腸直腸癌を有する患者の処置における抗ｐｄ−１抗体の使用 |
| CN109476753A (zh) | 2016-06-03 | 2019-03-15 | 百时美施贵宝公司 | 用于治疗肿瘤的方法的抗-pd-1抗体 |
| EP3601355A1 (en) | 2017-03-31 | 2020-02-05 | Bristol-Myers Squibb Company | Methods of treating tumor |
| KR20240149982A (ko) | 2017-06-01 | 2024-10-15 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 종양을 치료하는 방법 |
| EP3681535A1 (en) | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| US11351163B2 (en) | 2017-09-29 | 2022-06-07 | Bristol-Myers Squibb Company | Compositions and methods of treating cancer |
| CA3084370A1 (en) | 2018-01-12 | 2019-07-18 | Bristol-Myers Squibb Company | Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer |
| BR112020020826A2 (pt) | 2018-04-12 | 2021-01-19 | Bristol-Myers Squibb Company | Terapia de combinação anticâncer com anticorpo antagonista de cd73 e anticorpo antagonista do eixo pd-1/pd-l1 |
-
2016
- 2016-04-28 JP JP2017556651A patent/JP2018514550A/ja active Pending
- 2016-04-28 WO PCT/US2016/029877 patent/WO2016176503A1/en not_active Ceased
- 2016-04-28 KR KR1020177033882A patent/KR20170138555A/ko not_active Ceased
- 2016-04-28 KR KR1020247032661A patent/KR20240149980A/ko active Pending
- 2016-04-28 EP EP16725959.7A patent/EP3288982A1/en not_active Withdrawn
- 2016-04-28 US US15/141,769 patent/US10174113B2/en active Active
- 2016-04-28 EP EP21198377.0A patent/EP3988571A1/en active Pending
-
2019
- 2019-01-04 US US16/240,316 patent/US20190194328A1/en not_active Abandoned
-
2021
- 2021-03-09 JP JP2021037367A patent/JP2021105000A/ja active Pending
- 2021-11-10 US US17/523,702 patent/US12590153B2/en active Active
-
2024
- 2024-02-09 JP JP2024018579A patent/JP2024063023A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018514550A5 (https=) | ||
| JP2018515474A5 (https=) | ||
| US20250154257A1 (en) | Treatment of lung cancer using a combination of an anti-pd-1 antibody and an anti-ctla-4 antibody | |
| JP2023159353A (ja) | Ｔ細胞疲弊を予防および逆転するためのエピジェネティック標的および転写標的の同定 | |
| RU2017116847A (ru) | Антитела к pd-1 | |
| JP7164512B2 (ja) | Ｔｉｍ－４アンタゴニストとｐｄ－１アンタゴニストの組合せおよび使用方法 | |
| JP2018522887A5 (https=) | ||
| JP2018520657A5 (https=) | ||
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| CN107750167A (zh) | 用于治疗癌症和感染的免疫检查点调节剂的抑制剂 | |
| JP2018501197A5 (https=) | ||
| RU2018108048A (ru) | Новые анти-pd-1 антитела | |
| RS64268B1 (sr) | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora | |
| JP2019503387A5 (https=) | ||
| Faleiro et al. | Combined immune therapy for the treatment of visceral leishmaniasis | |
| KR20190008962A (ko) | 림프종 치료에서의 항-cd30 항체와 조합된 항-pd-1 항체의 용도 | |
| WO2018112407A1 (en) | Antibodies and methods for depleting regulatory b10 cells and use in combination with immune checkpoint inhibitors | |
| AU2019221672A1 (en) | Selective BCL-2 inhibitors in combination with an anti-PD- 1 or an anti-PD-L1 antibody for the treatment of cancers | |
| RS64388B1 (sr) | Pd-1 blokada nivolumabom kod refraktornog hočkinovog limfoma | |
| EP3743109A2 (en) | Mica/b antibodies and methods of use | |
| JP2023525664A (ja) | がんの処置のためのアルファ－２アドレナリン作動性受容体アゴニスト | |
| KR20180109977A (ko) | Il-17c에 대한 항체 | |
| JP2019534251A (ja) | Ｍｅｋ阻害剤、ｐｄ−１軸阻害剤、及びタキサンを用いた併用療法 | |
| WO2023034963A2 (en) | Combinations of immunotherapies and uses thereof | |
| US20240409653A1 (en) | Multispecific binding agents against pd-l1 and cd137 in combination with anti pd-1 antibodies for treating cancers |